Clearstone And Mitsubishi Announce Preferred Provider Relationship To Provide Clients Greater Access To Central Lab Services Throughout Asia-Pacific
Mitsubishi to access Clearstone's leading lab in China and the industry's most advanced scientific portfolio, and creates a new solution for Clearstone clients in Japan
Clearstone Central Laboratories, a leading global provider of central laboratory services for late-stage clinical trials, recently announced that it has entered into a partnership with Mitsubishi Chemical Medience Corporation (Mitsubishi), the market-leader in clinical and diagnostic laboratory testing services in Japan. This preferred provider relationship provides clients of both companies with seamless access to CAP-accredited laboratories for safety and specialty testing services throughout the Asia-Pacific region and around the world. The cross-collaboration opens access for Mitsubishi clients not only to Clearstone's leading lab in China but to its global laboratory network, and creates a new solution for Clearstone clients to access Mitsubishi's lab network in Japan.
"It has been most encouraging to watch our interactions and relationship develop over the last year, and we are very pleased to publicly announce the Mitsubishi partnership given the value and opportunities it creates for our clients", said Clearstone CEO Lewis Cameron. "Mitsubishi is a well established leader in Japan, and this agreement extends their reach and capabilities to other strategic markets, including our renowned laboratory in China. We look forward to aligning our operational and business development activities, as well as providing our clients with seamless access to the Japanese market".
"Pharmaceutical sponsors everywhere continue to look at new and emerging markets for drug development opportunities, and our clients are no different" said Mitsubishi Chemical Medience CEO Dr. Toshihiko Yoshitomi. "We are excited to be working closely with the market leader in China, and are confident our partnership with Clearstone will provide new channels of growth and competitive advantage for both companies".
This announcement follows a collaborative agreement that Clearstone signed with the Esoterix Clinical Trials Services division of LabCorp last year to provide clients access to the largest combined biomarker assay portfolio in the industry.
"We continue to look for unique and innovative solutions that help our clients streamline and accelerate their clinical research programs" added Cameron. "In this respect, Clearstone has become the preferred independent central lab of choice for many leading pharmaceutical and biotech companies".
About Clearstone
Clearstone Central Laboratories is the largest and most experienced private company exclusively focused on providing central lab services to support late-stage drug development with accurate and timely test data. With over 20 years of experience in mature and emerging markets, we offer world-class laboratory testing, project and data management, and logistical support to leading pharmaceutical and biotech companies around the world. Clearstone's 500-member global workforce delivers these services from our wholly-owned CAP-accredited laboratories and global kit production facilities in Beijing, Hamburg, Paris, Singapore and Toronto. We also own and operate APOLLO CLPM – the leading proprietary central laboratory protocol management system. For more information, visit www.clearstonelabs.com.
About Mitsubishi
Mitsubishi Chemical Medience is the first company in Japan to establish a business style that combines clinical and diagnostic laboratory testing services with IVD business and Drug Development Support business. Within the Drug Development Support business Mitsubishi Chemical Medience is capable of seamless services with non-clinical and clinical testing and operates the largest CAP accredited lab dedicated to clinical trial. Non-clinical and clinical testing laboratories are located in Kamisu city and Tsukuba city of Ibaraki prefecture, Itabashi of Tokyo and Uto of Kumamoto prefecture. For more information, visit www.medience.co.jp.
SOURCE: Clearstone Central Laboratories